Generic Name: siponimod
Brand Name: Mayzent
Manufacturer: Novartis Pharmaceuticals Canada Inc.
Indications: Secondary progressive multiple sclerosis
Manufacturer Requested Reimbursement Criteria1: For the treatment of patient with secondary progressive multiple sclerosis.
Submission Type: New
Project Status: Active
Companion Diagnostics: No
Fee Schedule: Schedule A
- The requested reimbursement criteria are provided by the applicant and do not necessarily reflect the views of CADTH. Reimbursement criteria from CADTH will be documented in the final recommendation, if applicable.
|Call for patient input posted||August 28, 2019|
|Patient group input closed||October 18, 2019|
|Patient input summary sent for review to patient input groups||-|
|Patient group comments on input summary closed||-|
|Submission received||September 26, 2019|
|Submission accepted for review||October 10, 2019|
|Review initiated||October 11, 2019|
|Draft CADTH review report(s) sent to sponsor||January 02, 2020|
|Comments from sponsor on draft CADTH review report(s) received||January 13, 2020|
|CADTH review team's comments on draft CADTH review report(s) sent to sponsor||February 06, 2020|
|Canadian Drug Expert Committee (CDEC) meeting||February 19, 2020|
|CDEC recommendation sent to sponsor and drug plans||March 02, 2020|
March 04, 2020